Lung cancer is one of the leading cancer malignancies, with a five-year survival rate of only ∼15%. We have developed a lentiviral-vector-mediated mouse model, which enables generation of non-small-cell lung cancer from less than 100 alveolar epithelial cells, and investigated the role of IKK2 and NF-κB in lung-cancer development. IKK2 depletion in tumour cells significantly attenuated tumour proliferation and significantly prolonged mouse survival. We identified Timp1, one of the NF-κB target genes, as a key mediator for tumour growth. Activation of the Erk signalling pathway and cell proliferation requires Timp-1 and its receptor CD63. Knockdown of either Ikbkb or Timp1 by short hairpin RNAs reduced tumour growth in both xenograft and lentiviral models. Our results thus suggest the possible application of IKK2 and Timp-1 inhibitors in treating lung cancer.
Inflammation and nuclear factor-κB (NF-κB) activation have long been linked to cancer development 1 . Recent studies have indicated the involvement of NF-κB in v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (Kras)-mutation-induced lung adenocarcinoma [2] [3] [4] . Expressing IκBαM super-repressor or conditional-knockout p65 in the tumour cells significantly reduced tumour size and tumour incidence. In addition, ablation of IKK2 in myeloid cells inhibited tobacco-smokeinduced lung-tumour promotion and malignant-cell proliferation in the Kras LA2 model 5 . A very recent study has also indicated the involvement of NF-κB in epidermal growth factor receptor tyrosine kinase inhibitor resistance 6 . IKK2, as the essential kinase for NF-κB activation, is thus thought to be a good candidate for drug design [7] [8] [9] . Lung cancers along with other human cancers are initiated from a few cells bearing certain mutations that give growth advantage [10] [11] [12] [13] . Previous studies have indicated that different cell origins are responsible for different subtypes of lung cancer 14 . These tumour-initiating cells are surrounded by normal cells and this microenvironment is critical for studying tumour development. Mouse tumour models based on crossing a conditional allele of the tumorigenic element with tissue-specific Cre recombinase may not aptly reflect the real tumour initiation, as the genetic lesions usually take place in the whole organ 15, 16 . We used lentiviral vectors for establishing tumours in mice for the following reasons: (1) lentiviruses infect almost any type of cell, and transgene expression can be controlled by a tissue-specific promoter, which enables a more precise tracing of the origin of the cancer cell; (2) lentiviruses integrate into genomic DNA so that it is possible to stably deliver oncogenes and short hairpin RNAs (shRNAs) against tumour suppressors, and bypass the requirement of numerous conventional genetic crossings; (3) viral titres can be controlled to infect only a few cells, to more faithfully recapitulate human cancer initiation 17 . Moreover, in principle, a lentiviral vector carrying certain oncogenes and shRNAs against tumour suppressors is sufficient to initiate tumorigenesis in a mouse of any genomic background, although in this study we used a series of tissue-specific Cre-expressing lentiviral vectors to initiate tumours in LSL-Kras G12D mice 18 , for biosafety considerations. In the present study, we have investigated the underlying mechanisms involved in NF-κB promoting lung-cancer cell proliferation by knocking out inhibitor of kappaB kinase beta (Ikbkb, also known as IKK2) specifically in tumour cells. We found that downregulation of Timp1 (tissue inhibitor of metalloproteinase 1), one of the NF-κB target genes, contributed to slower tumour-cell proliferation, consistent with the fact that NF-κB and Timp-1 are usually highly expressed in advanced lung-cancer patients with poor prognosis 19, 20 . Furthermore, knocking down Ikbkb or Timp1 with shRNAs in tumour cells significantly reduced Erk activation and cell proliferation, thereby attenuated tumour progression in our mouse model. 
RESULTS

Mouse lung-cancer model mediated by lentiviral vectors
We developed a set of lentiviral vectors that can induce oncogenic mutations in a small number of lung epithelial cells and initiate lung cancer in mice. As shown in Fig. 1a , a typical lentivector for this purpose has a combination of a tissue-specific oncogene (or Cre) and several shRNAs to knock down tumour-suppressor genes. We successfully induced lung adenoma and adenocarcinoma in the LSL-Kras G12D mouse with carbonic anhydrase 2 (CA2)-driven Cre lentiviral vector ( Supplementary Fig. S1b) . Notably, the result from CA2-Cre virus infection in LSL-Rosa26 lacZ reporter mice indicated that the CA2 promoter is expressed mainly in alveolar epithelial cells 21 and the tumours were initiated in very few cells tranduced by lentiviral vectors (Supplementary Fig. S1a ).
Transduction by lentiviral vectors generating shRNA against p53 (U6-shp53) significantly accelerated tumour progression and resulted in rapid development of adenocarcinomas with more advanced tumour grading (Fig. 1b) . Figure 1c -e shows the evolution of tumour lesion from an atypical adenomatous hyperplasia to small adenoma and to advanced adenocarcinoma 22 . Twelve weeks after infection, the majority of the tumour lesions reached grade 3 and grade 4, showing pleomorphic nuclei and aberrant mitosis (Fig. 1f) . More importantly, massive stromal cell infiltration was found in ∼20% of the advanced tumours, which recapitulates well the pathology observed in human malignancies (Fig. 1g,h ). All tumours we have analysed in the CA2Cre-shp53 lentiviral model were typical adenocarcinomas with SPC (pro-surfactant protein C)-positive and CC10 (Clara-cell-specific antigen)-negative staining patterns (Fig. 1i,j) . The Ki-67-positive rate is 5-20% in these tumours, which is similar to what has been reported in human adenocarcinomas 23 ( Fig. 1k) .
Ikbkb knockout in tumour cells impairs tumour proliferation
Given that the NF-κB pathway plays an important role in tumour development and that IKK2 is the seminal kinase responsible for NF-κB pathway activation, we were particularly interested in exploring the therapeutic potential of IKK2 inhibition in non-small-cell lung cancers. We therefore crossed IKK2 Fig. 2a ). At 100 days post lentiviral infection, the average tumour burden in IKK2 −/− mice was only about one-third to one-half of that in wild-type mice (Fig. 2b) .
Although IKK2 −/− mice had less tumour burden than wild-type mice when collected at an early time, they developed comparable tumours at the endpoint (Fig. 2b,c) . The tumours found in both genotypes of mice were adenocarcinomas, exhibiting SPC-positive and CC10-negative staining (Fig. 2d,e) . Similar percentages of the tumour areas were scored positive for Erk phosphorylation (Erk-p), indicating their advanced tumour stage 24, 25 (Fig. 2f) . As, in various cancers, inflammatory-cell infiltration stimulates tumour growth, we hypothesized that IKK2-deficient tumours might produce less chemokines and attract fewer inflammatory cells. We therefore analysed inflammatory-cell infiltration in the bronchioalveolar lavage at different times after tumour initiation. Macrophage counts from wild-type mice increased significantly during the three months of tumour development. IKK2 −/− mice showed less macrophage infiltration for the first three months; however, the cell numbers were similar to those found in wild-type mice at the endpoint, suggesting that inflammatory-cell infiltration was correlated with the size of the tumour burden instead of the IKK2 status of the tumour (Fig. 2g,l) . This might be due to the fact that tumour-surrounding tissues were IKK2 wild type, which could compensate for chemokine production when inflamed by nearby tumour formation. These results rule out the possibility that the IKK2 −/− mice developed fewer and smaller tumours owing to reduced macrophage chemotaxis and inflammation.
To investigate the real contribution of IKK2 and the NF-κB pathway in this lung-cancer model, we examined other possible roles of NF-κB, such as pro-proliferation, anti-apoptosis and pro-angiogenesis. We were unable to find any significant differences between IKK2
−/− and wild-type tumours regarding the apoptotic marker (cleaved caspase 3) or vascular endothelial marker (von Willebrand factor; Fig. 2h,g ). In contrast, we found surprisingly high staining of proliferation markers Ki-67 and PCNA in wild-type tumours (12% Ki-67 positive in wild-type tumours versus 6% in IKK2 −/− tumours at 11 weeks, and Table S1 ). Taken together, these results indicate that the most likely major contribution of NF-κB pathway in our lung-cancer model is pro-proliferation.
NF-κB activation in lung cancer
Constitutive NF-κB activation has been reported in various tumours, including different forms of lung cancer 26 . Therefore, we next examined NF-κB activity in our primary lung-tumour samples. Nuclear extracts from wild-type tumours showed high NF-κB binding activity, whereas IKK2 −/− tumours remained at a basal level. Supershift using specific antibodies confirmed the bands as canonical NF-κB dimers containing p65 and p50, but not c-Rel (Fig. 3a) . We next asked whether oncogenic stress induced by Kras G12D is responsible for NF-κB activation in these cells. Using a tetracycline-response element (TRE)-regulated Kras-expressing system, we detected high NF-κBactivity within 3-4 days of Kras G12D expression ( Supplementary Fig. S3a ). Kras expression upregulated the PI3K-Akt and MEK-Erk pathways, as well as the DNA-damage response, which all activated the NF-κB pathway 27, 28 ( Fig. 3b and Supplementary Fig. S3b-d) . In addition, inhibitors of MEK, PI3K and ATM all suppressed the NF-κB reporter activity induced by Kras (Fig. 3c) .
As anticipated, IKK2 was required for the NF-κB activation by Kras, as Ikbkb shRNA knockdown as well as the small-molecule inhibitor TPCA-1 significantly reduced NF-κB activity. Furthermore, p53 shRNA knockdown resulted in higher NF-κB activity (Fig. 3d) , consistent with a previous report 4 . All these results supported the idea that oncogenic Kras, together with p53 deficiency, contributed to NF-κB activation in these tumour cells.
Timp-1 is one of the mediators for NF-κB-induced tumour proliferation
We next sought to elucidate how NF-κB contributed to tumour proliferation. Multiple NF-κB-regulated cytokines stimulate tumourcell proliferation through autocrine and paracrine pathways 29 . We thus investigated the expression of a set of 40 cytokines in wild-type and IKK2
−/− tumour lysates using an antibody array, and further verified by using quantitative PCR with reverse transcription (RT-PCR) ( Supplementary Fig. S4a-c) .
Timp-1 was identified among the cytokines that were significantly downregulated in the IKK2 −/− tumour lysate. We also saw reductions in the levels of some other cytokines (IL-23 and TREM-1; Supplementary Fig. S4b) ; however, their protein levels were very low in the tumour lysates and could not be detected in cell cultures derived from the tumours, indicating that they might be from tumour-infiltrating inflammatory cells. Interestingly, Timp1 has been reported to be expressed in different human tumours, including lung adenocarcinomas 30 . Although the role of Timp-1 in cancer growth and metastasis is controversial 31 , high Timp1 expression levels are always linked to poor prognoses in lung-cancer patients 19, 20 . The Timp1 gene promoter has putative NF-κB binding sites 32 , so its expression could be suppressed by the IκBαM super-repressor, or Ikbkb shRNA, in wild-type tumour cells (Fig. 3e) . The difference of Timp1 expression in primary wild-type and IKK2 −/− tumours was then further verified at messenger RNA and protein levels ( Fig. 3f-h; Supplementary Fig. S4e ).
These observations led to the question of whether high Timp1 expression in wild-type tumours contributes to their rapid proliferation in vivo. To address this question, we examined tumour-cell growth in a subcutaneous xenograft model in nude mice using two cell lines derived from wild-type and IKK2
−/− primary tumours, respectively. Wild-type line 4A3 formed a much larger tumour mass than did IKK2 −/− line 1D3, within three weeks after transplantation. Knocking down either Ikbkb or Timp1 expression in 4A3 reduced tumour size considerably (Fig. 3i) . Although ectopic expression of Ikbkb in line 1D3 completely rescued its proliferation as judged by the size of the tumours (Fig. 3j) , surprisingly, ectopic expression of Timp1 did not significantly influence tumour size. It thus seems that IKK2 and NF-κB play an essential role in tumour-cell proliferation, whereas Timp-1 may be a necessary but not sufficient mediator of this effect.
Timp-1 stimulates cell proliferation through the Erk pathway
There is increasing evidence indicating that Timp-1 has paradoxical effects on tumour growth 31, 33 . When Kras G12D was expressed in U2OS cells, significant activation of Erk, Akt and NF-κB pathways was observed, together with upregulation of Timp1 expression ( Fig. 4a;  Supplementary Fig. S5a,b) . Given that the Erk pathway is critical for cell proliferation, we asked whether Timp1 expression stimulates cell proliferation in a positive-feedback loop through Erk activation. Interestingly, Erk but not Akt phosphorylation was severely impaired when Ikbkb was knocked down in U2OS cells (Fig. 4a) . Moreover, doxycycline (Dox)-induced expression of Timp1 completely rescued the defect of Erk phosphorylation in Ikbkb-knockdown cells, which had low endogenous Timp1 induction owing to lack of NF-κB activation (Fig. 4a) . Similarly, an Erk phosphorylation defect was seen in Timp1-knockdown cells (Supplementary Fig. S5c ). These results point to a positive-feedback loop: Kras G12D -Erk-p-NF-κB-Timp-1-Erk-p, which might play an important role in tumour-cell proliferation.
We next examined this effect in cell lines derived from IKK2
tumour, which show low Timp1 expression and slow proliferation. When ectopic Timp1 expression in these cells was turned on by addition of Dox, both Erk phosphorylation and cell proliferation, determined by BrdU incorporation, were substantially increased (Fig. 4b,c) . Importantly, the increase of cell proliferation by Timp-1 could be abolished by adding MEK inhibitor PD0325901, which further supports our contention that the Erk pathway mediates the pro-proliferation effect of Timp-1 (Fig. 4c) .
Indeed, there was higher Timp1 expression in wild-type tumours than in IKK2 −/− tumours at all stages of tumour development, owing to NF-κB activation ( Supplementary Fig. S4e) , correlating with the rapid proliferation and high percentage of Erk-p staining observed in wild-type tumours, compared with IKK2 −/− tumours (Fig. 4d) . Although the majority of the IKK2 −/− tumours at the endpoint showed elevated Erk-p staining, as observed with wild-type tumours ( Supplementary Fig. S5d ), clear differences could be observed in tumours collected 11 weeks after lentiviral infection and stable cell lines derived from the tumours (Fig. 4d,e and Supplementary Fig.  S5d,e) . p19ARF was also found at low levels in IKK2 −/− tumours, owing to the low Erk activation (Fig. 4e, tumours 3, 4 and 5, and Supplementary Fig. S5e ). Overall, Erk phosphorylation was found in ∼30% of wild-type tumour lesions, as compared with less than 10% in IKK2
−/− tumours. These results clearly indicate a critical role for IKK2 and Timp-1 in maintaining high proliferation and advanced pathology in lung cancers.
Activation of the Erk pathway by Timp-1 requires CD63
As Timp-1 was originally identified as a tissue inhibitor of metalloproteinases (MMPs), we first asked whether this inhibitory property is responsible for the its pro-proliferation activity. Addition of recombinant Timp-1 protein (rTimp-1) to IKK2 −/− tumour cells precipitously increased both focal adhesion kinase (FAK) and Erk phosphorylation, whereas the potent MMP inhibitor GM6001 had no effect (Fig. 5a) . Furthermore, unlike rTimp-1, GM6001 failed to stimulate cell proliferation in the BrdU incorporation assay (Fig. 5b) . These results indicate that Timp-1's function in cell proliferation is independent of its MMP inhibitor activity.
It has previously been shown that Timp-1 can bind to CD63, a member of the tetraspanin family, and activate its downstream pathways including FAK and Erk phosphorylation 34 . We used two shRNAs to knock down Cd63 expression in the IKK2 −/− tumour cells (Fig. 5c ) and checked if Cd63 knockdown would eliminate the effect of Timp-1 treatment. As shown in Fig. 5d ,e, Timp-1-induced Erk phosphorylation and cell proliferation were impaired in Cd63 shRNA 1 and Cd63 shRNA 2 cells, but not in control shRNA cells. Finally, FAK inhibitor (FAK I-14) successfully repressed Erk phosphorylation induced by ectopic Timp1 expression, supporting a link in the signal transduction from CD63 to FAK and Erk (Fig. 5f ). Our cumulative results confirm that binding of Timp-1 to CD63 and activation of downstream signal transduction are crucial for its pro-proliferation effect.
Timp1 knockdown recapitulates IKK2 deficiency in lung-cancer progression
To further confirm the importance of IKK2 and Timp-1 in lung adenocarcinoma progression in vivo, we designed a set of lentiviral vectors that included shRNAs against Ikbkb or Timp1 (Fig. 6a) . We then applied these vectors to initiate lung tumours, and followed their growth. When tumours were collected after the same inoculation time, we observed reduced tumour size from the groups of mice transduced with Ikbkb and Timp1 shRNA vectors (Fig. 6b) . Immunostaining confirmed that Ikbkb shRNA and Timp1 shRNA tumours had less Timp1 expression, less Erk phosphorylation and lower Ki-67 percentage as compared with controls (Fig. 6b,c) . Mice receiving either Ikbkb or Timp1 shRNA vectors consistently survived much longer than those receiving control vectors (202 days and 192 days versus 129 days median survival time, Fig. 6d ). All these results strongly support the possibility of designing inhibitors that target IKK2 or Timp-1 for treatment of lung adenocarcinomas.
As proof of principle, we tested the effect of TPCA-1, a preclinical IKK2 inhibitor 35, 36 , in treating lung cancer in our mouse model. We induced tumours in Kras G12D Rosa26 luc mice with CA2Cre-shp53 lentivirus and initiated therapy 10 weeks after viral infection for 6 weeks (Fig. 7a) . The luciferase imaging results indicated that TPCA-1 treatment led to slower tumour growth when compared with vehicle control (Fig. 7b,c) . We were not able to continue treatment during the whole tumour development, owing to the toxicity of chronic NF-κB inhibition; however, administration of TPCA-1 for 6 weeks already increased the median survival time from 141 days to 153 days, with statistical significance (P = 0.0007 by log-rank test), indicating high therapeutic potential of IKK2 inhibition (Fig. 7d) . Although we have not been able to test Timp-1-neutralizing antibodies in treating primary mouse lung cancer owing to the lack of reagents, follow-up experiments using Timp-1 antibodies or inhibitors will hopefully offer opportunities of treating lung cancer.
DISCUSSION
In this study, we have described a mouse lung-cancer model mediated by lentiviral vectors. Compared with the widely used adeno-Cre vector 18 , the lentiviral vectors used here give more versatility in terms of tissue specificity, viral titre and sustained expression of genes and shRNAs to be delivered. In the Rosa26 lacZ reporter mouse experiment, we found that fewer than 100 cells were transduced and gene expression was observed when 5 × 10 4 lentiviral particles carrying CA2Cre were given intratracheally ( Supplementary Fig. S1a ). The tissue-specific promoter enables tumour initiation from a defined type of cell, which makes it possible to trace the cellular origins of different types of lung cancer.
NF-κB is a major anti-apoptotic transcription factor, and its activation has been investigated in different types of human cancer 1, 7 . It is not surprising that inhibition of NF-κB activity impairs tumour progression. However, the role of NF-κB in cancer is apparently more than anti-apoptotic. Several groups have reported tumour inhibition when NF-κB activity was abolished in lung-cancer cells by removing p65 (ref. 3) or IKK2 (this study), or by overexpressing IκBαM (ref. 4) . Contrary to expectation, none of these groups identified changes in classic anti-apoptotic gene expression when NF-κB was inhibited (Supplementary Fig. S4d ). In contrast, we observed significant decrease of cell-proliferation markers (both Ki-67 and PCNA) in IKK2 −/− tumours. Consistent with this result, we identified predominantly changes of cell-cycle profiling in microarray analysis of wild-type and IKK2 −/− tumour samples ( Supplementary Fig. S2d and Table S1 ), and, impressively, the changes of cell-cycle-related genes could be rescued in the IKK2 −/− tumour cells by IKK2 reconstitution (Supplementary Fig. S2e ).
In the search for NF-κB target genes that are related to stimulating cell proliferation, we have identified Timp1. In both in vitro and in vivo assays, Timp-1 showed pro-proliferation activity by maintaining high Erk activation. It is worth mentioning that Erk activation has been found in mouse lung adenocarcinomas at advanced stage 24, 25 ( Supplementary Fig. S5d ). Furthermore, complete Erk1 and Erk2 ablation eliminated Kras G12V -induced lung cancers 37 . In experiments reported here, Timp1 or Ikbkb knockdown in tumour cells markedly reduced Erk phosphorylation, and hence impaired tumour proliferation (Fig. 6) . These results identify an important role of NF-κB as well as Timp-1 in maintaining Erk activation and accelerating lung-cancer progression. Clearly in our model, depletion of IKK2 impaired the progression of all tumours carrying p53, p16INK4a, Pten or Lkb1 shRNA ( Supplementary Fig. S6 ). Actually, NF-κB has been found to be aberrantly upregulated in a large number of human cancers 1, 8 , and targeting NF-κB with small molecules for the treatment of cancer as well as other diseases has attracted much attention in the past decades. However, safety and efficacy are still of concern owing to the involvement of NF-κB in so many biological activities 8, 38 . Our work of identifying target genes of NF-κB that mediate its role in tumour development may offer an alternative approach . For example, Timp-1 inhibition reduced tumour size and prolonged animal survival, similarly to what is seen with IKK2 inhibition in our mouse model (Fig. 6b,d) , so developing Timp-1-neutralizing antibodies or inhibitors that can abolish its pro-proliferation role may be an attractive alternative to IKK2 inhibition and probably has fewer side-effects. Our study indicates that the pro-proliferation function of Timp-1 relies on the presence of CD63 (Fig. 5) . Thus, future work of developing Timp-1 antibodies and inhibitors should focus on its carboxy-terminus region that is required for binding to CD63 (refs 34,39) . The preclinical studies on Timp-1 inhibition will definitely benefit those lung-cancer patients carrying Kras mutations, against which there is no effective therapeutic strategy available at present. The version of this Article originally published should have acknowledged that this work was also supported by NIH grant number CA158191. This has been corrected in all online versions of the Article.
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